Latest Articles
Prescription charges frozen in England - Asian Leader
Prescription charges frozen in England Asian Leader
Published: May 7, 2025, 9:35 p.m.
Endometriosis 101: A Disease Profile - Managed Healthcare Executive
Endometriosis 101: A Disease Profile Managed Healthcare Executive
Published: May 7, 2025, 8:59 p.m.
Endometrial Cancer Phase III Shows Molecular Profiling Personalizes Treatment - Inside Precision Medicine
Endometrial Cancer Phase III Shows Molecular Profiling Personalizes Treatment Inside Precision Medicine
Published: May 7, 2025, 6:12 p.m.
Endometrial Cancer Phase III Shows Molecular Profiling, Personalizes Treatment - Inside Precision Medicine
Endometrial Cancer Phase III Shows Molecular Profiling, Personalizes Treatment Inside Precision Medicine
Published: May 7, 2025, 6:12 p.m.
Jill Biden lands new job following four years as first lady - FOX 5 New York
Jill Biden lands new job following four years as first lady FOX 5 New York
Published: May 7, 2025, 4:07 p.m.
Jill Biden lands new job following four years as first lady - New York Post
Jill Biden lands new job following four years as first lady New York Post
Published: May 7, 2025, 3:03 p.m.
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids - BioSpace
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids BioSpace
Published: May 7, 2025, 1:28 p.m.
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids - The Manila Times
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids The Manila Times
Published: May 7, 2025, 12:24 p.m.
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids - PR Newswire
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids PR Newswire
Published: May 7, 2025, noon
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids - 스페셜타임스
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids 스페셜타임스
Published: May 7, 2025, noon
Link copied to clipboard!